Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc

CRBP

0.00

Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ: CRBP) with a Outperform and raises the price target from $40 to $44.